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Abstract
Background: In the search for novel antibody-drug conjugates (ADCs) with therapeutic potential, it is imperative to
identify novel targets to direct the antibody moiety. CD13 seems an attractive ADC target as it shows a differential
pattern of expression in a variety of tumors and cell lines and it is internalized upon engagement with a suitable
monoclonal antibody. PM050489 is a marine cytotoxic compound tightly binding tubulin and impairing
microtubule dynamics which is currently undergoing clinical trials for solid tumors.
Methods: Anti-CD13 monoclonal antibody (mAb) TEA1/8 has been used to prepare a novel ADC, MI130110, by
conjugation to the marine compound PM050489. In vitro and in vivo experiments have been carried out to
demonstrate the activity and specificity of MI130110.
Results: CD13 is readily internalized upon TEA1/8 mAb binding, and the conjugation with PM050489 did not have
any effect on the binding or the internalization of the antibody. MI130110 showed remarkable activity and
selectivity in vitro on CD13-expressing tumor cells causing the same effects than those described for PM050489,
including cell cycle arrest at G2, mitosis with disarrayed and often multipolar spindles consistent with an arrest at
metaphase, and induction of cell death. In contrast, none of these toxic effects were observed in CD13-null cell
lines incubated with MI130110. Furthermore, in vivo studies showed that MI130110 exhibited excellent antitumor
activity in a CD13-positive fibrosarcoma xenograft murine model, with total remissions in a significant number of
the treated animals. Mitotic catastrophes, typical of the payload mechanism of action, were also observed in the
tumor cells isolated from mice treated with MI130110. In contrast, MI130110 failed to show any activity in a
xenograft mouse model of myeloma cells not expressing CD13, thereby corroborating the selectivity of the ADC to
its target and its stability in circulation.
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Conclusion: Our results show that MI130110 ADC combines the antitumor potential of the PM050489 payload with
the selectivity of the TEA1/8 monoclonal anti-CD13 antibody and confirm the correct intracellular processing of the
ADC. These results demonstrate the suitability of CD13 as a novel ADC target and the effectiveness of MI130110 as
a promising antitumor therapeutic agent.
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Introduction
CD13, also known as aminopeptidase-N (APN) and alanyl
aminopeptidase (ANPEP) (EC 3.4.11.2; UniProt P15144), is a
metallopeptidase originally described as a myeloid-specific
hematopoietic marker [1]. It is a moonlighting ectoenzyme
engaged in a wide range of biological functions (reviewed in
[2]), most notably being involved in the post-secretory pro-
cessing of secreted signaling peptides, regulating their access
to cellular receptors. There are a number of results support-
ing the role of CD13 in tumor growth and metastasis [3, 4]
as well as in angiogenesis [5, 6]. CD13 has been shown to be
expressed in vessels of most neoplastic tissues as well as in
tumor stroma [7]. Consistent with this, CD13 deficiency
hampers tumor vascularization [4]. In addition, there is
evidence showing a critical role of CD13-positive bone
marrow-derived myeloid cells in supporting tumor growth,
angiogenesis, and metastasis [8], thus highlighting CD13 as a
potential antitumor target [9]. Besides, high expression of
CD13 in cancer cells is associated with bad prognosis and
poor patient survival in pancreas [10] and colon cancers [11],
non-small cell lung cancer [12, 13], malignant pleural meso-
thelioma [14], hepatoblastoma [15], and soft tissue sarcoma
[16] among others. In addition, CD13 has been shown to be
a target for myeloid malignancies [17].
Antibody-drug conjugates (ADCs) are a class of thera-
peutic entities whose relevance in cancer treatment is en-
dorsed by the successful cases of brentuximab vedotin and
trastuzumab emtansine (Adcetris and Kadcyla, both regarded
as remarkable milestones in the fight against Hodgkin’s
lymphoma and breast cancer, respectively). New ADCs have
been recently approved by the Food and Drug Administra-
tion (FDA) for the treatment of a variety of lymphoid malig-
nancies, such as ozogamicin conjugates to gemtuzumab
(Mylotarg), inotuzumab (Besponsa), approved by the FDA in
2017, and the most recent ADC examples moxetumomab
pasudotox (Lumoxiti) and polatuzumab vedotin (Polivy), ap-
proved in 2018 and 2019, respectively (see [18, 19] for recent
reviews). The successful cases of these ADCs have propelled
efforts to discover and develop new conjugates as exempli-
fied by the large number of clinical trials involving ADCs, ex-
ceeding 100 at the beginning of 2019 [20]. To expand the
success of these four ADCs, it is imperative to identify novel
antibody targets fulfilling the requirements needed for such a
role: high expression on the tumor cell surface, differential
expression in tumor versus normal cells, susceptibility to
bind to a suitable antibody, and appropriate internalization
rate as well as adequate intracellular trafficking [21]. In fact,
some authors consider the antibody target as the most crit-
ical factor in the development of an active, therapeutically
relevant ADC [22].
Considering the body of evidence described above and
the fact that CD13 internalization can be achieved by
using the CD13-binding Asn-Gly-Arg (NGR) tripeptide
[4] and anti-CD13 monoclonal antibodies (mAb) [23, 24],
CD13 may well be deemed as a suitable target for novel
ADCs. However, it is not known whether the complex
formed by CD13 and a suitable ADC would be efficiently
internalized and processed intracellularly. We have re-
cently published the successful use of PM050489, a mar-
ine molecule capable of binding tubulin at a novel site
with nM affinity [25, 26], to prepare an ADC using a non-
cleavable linker and the resulting conjugate MI130004 ex-
hibited outstanding activity in several murine xenograft
models for human tumors [27]. Prompted by this success-
ful experience and urged by the curiosity to explore the
potential of CD13 as a novel ADC target, we have conju-
gated PM050489 to a monoclonal anti-CD13 antibody
and have investigated the biological effects of this ADC,
called MI130110, in vitro as well as in in vivo models.
Materials and methods
Reagents
PM050489, PM120160 (the result of adding a non-
cleavable linker to PM050489 as depicted in Fig. 1a, syn-
thetic process described in [27]), and MI130110 were pre-
pared in PharmaMar S.A. Chromatography reagents and
materials were from GE Healthcare (Buckinghamshire,
UK). Unless otherwise stated, reagents were purchased
from Sigma-Aldrich (St Louis, MO). Given the null absorb-
ance of PM120160 at 280 nm, antibody and ADC concen-
trations were determined spectrophotometrically by
monitoring their absorbance at such wavelength using a
molar extinction coefficient of 2.18E05M−1 cm-1, a typical
value for IgGs [28], and a molecular weight of 150 kDa.
Preparation of the anti-CD13 TEA1/8 monoclonal
antibody
The anti-CD13 TEA1/8 mAb was obtained in our la-
boratory using a hybridoma obtained from a fusion of
SP2 mouse myeloma cells with splenocytes isolated from
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mice that had been immunized with human endothelial
cells isolated from umbilical cord. TEA1/8 was clustered
as an anti-CD13 antibody in the IV International
Leukocyte Typing Workshop [29]. A detailed description
of the methodology is provided in the supplementary
information.
Preparation and analysis of MI130110
A detailed description of the conjugation of PM120160
to TEA1/8 mAb is provided in Supplementary informa-
tion. The resulting MI130110 ADC was purified by gel
filtration in Sephadex G-25. ADC concentration was de-
termined by spectrophotometry. Analysis of MI130110
by hydrophobic interactions chromatography (HIC) was
performed on an Agilent 1100 HPLC system (Agilent,
Santa Clara, CA) (see Supplementary information).
Flow cytometry
For the analysis of CD13 expression, cells (1E07 cells/
mL) were incubated in the presence of 10 μg/mL anti-
CD13 TEA1/8 mAb or MI130110 or the corresponding
isotype control for 30 min at 4 °C. After washing with
Fig. 1 MI130110 structure and CD13 expression profile in cells. a Structure of MI130110, PM050489, and PM120160. b HT1080, NB-4, U-937, RPMI
8226, EA.hy926, and Raji cells (1E06) were incubated in the presence of TEA1/8 mAb (10 μg/mL) or the corresponding isotype control. After
washing, cells were labeled with rabbit anti-mouse FITC and analyzed by flow cytometry
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cold phosphate buffered saline (PBS) at 400 g for 5 min,
cells were incubated with rabbit anti-mouse-fluorescein
isothiocyanate (FITC) antibody for 20 min at 4 °C,
washed and analyzed by flow cytometry in a FACS
Canto II cytofluorimeter (BD Biosciences). Cells from
xenografted tumors were prepared as described in Sup-
plementary information and analyzed by flow cytometry
as described above.
To assess the internalization of the CD13 with either
TEA1/8 mAb or MI130110, cells (1E07 cells/mL) were
cultured in the presence of anti-CD13 TEA1/8 mAb or
MI130110 or the corresponding isotype control at the
indicated concentrations and times at 37 °C, in order to
allow the endocytosis of the naked and conjugated anti-
CD13 mAb. After washing with cold PBS at 40×g for 5
min, cells were labeled with rabbit anti-mouse FITC for
20 min at 4 °C. Then, cells were washed and analyzed by
flow cytometry. Cells labeled with isotype control were
used as negative control. The percentage of endocytosis
was calculated as the decrease of mean fluorescence in-
tensity (MFI) of CD13 staining after incubation at 37 °C
relative to the CD13 MFI at 0 h.
Cell cycle analysis
HT1080 and EA.hy926 cells (2E06 cells/mL) were cul-
tured in the presence or in the absence of different con-
centrations of MI130110. After the indicated times, cells
were harvested, fixed in ethanol, and stained with propi-
dium iodide (PI) as previously described [30]. Cell cycle
was analyzed by flow cytometry and the ModFit LT soft-
ware (Verity Software House, Topsham, ME).
Cell viability assay
A colorimetric assay based on the reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) was used for quantitative measurement of cell
viability as already described [27].
Cell death determination
Cells (1E05 per well) were cultured in 96-well microtiter
plates in the presence or in the absence of increasing
concentrations of MI130110. After 24, 48, and 72 h, cells
were harvested and incubated with FITC-labeled
annexin V (Immunostep, Salamanca, Spain) and 1 μg/
mL PI (Sigma-Aldrich) in binding buffer (5 mM CaCl2,
10 mM Hepes, and 140 mM NaCl). After 15 min in the
dark, they were analyzed by flow cytometry. Cell viability
was measured as the percentage of annexin V and PI-
double negative cells.
Immunofluorescence
For fluorescence microscopy analyses HT1080, cells (1E05)
were seeded onto poly-lysine-coated coverslips and cul-
tured overnight at 37 °C and 5% CO2 atmosphere. Then,
cells were incubated with 5 μg/mL of either anti-CD13
TEA1/8 mAb or MI130110 (IgG2a) and either kept on ice
for at least 30min or cultured at 37 °C for 3 h or 24 h to
allow CD13 endocytosis, as indicated. For detection of
CD13, cells were fixed with 1:1 (v/v) methanol/acetone,
washed three times with cold PBS, and blocked with 10
mM Hepes, pH 7.4, 3% bovine serum albumin (BSA), and
100 μg/mL γ-globulin in PBS for 1 h at 37 °C. CD13 stain-
ing was achieved by incubating cells with Alexa 488-labeled
rabbit anti-mouse antibodies for 1.5 h at 37 °C. For the ana-
lysis of mitosis, 0.75x1E5 HT1080 cells were fixed with neu-
tral buffered 10% formalin solution for 10min, washed and
then blocked and permeabilized with buffer containing 10
mM Hepes, pH 7.4, 0.3% triton X-100, 3% BSA and 2%
goat serum in PBS for 1 h at 37 °C. For mitosis analysis,
cells were stained with anti-β-tubulin (IgG1, TUB2.1,
Sigma) and either with α-tubulin (IgG2b, 66031-1-Ig, Pro-
teintech) or with anti-acetylated α-tubulin (IgG2b, 6-11B-1,
Sigma) in blocking buffer for 1.5 h at 37 °C. Then, cells
were carefully washed with PBS 3 times and then incubated
with anti-mouse IgG1-Alexa 488, anti-mouse IgG2b-Alexa
647, and with anti-mouse IgG2a-Alexa 594 (to detect endo-
cyted CD13-complexes with either TEA1/8 or MI130110)
in blocking buffer for 1.5 h at 37 °C. Nuclei and chromo-
somes were visualized by staining with 10 μg/mL of 4′,6-
diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) for 10
min at room temperature, and samples were then mounted
on slides using Prolong (Thermo-Fisher Scientific). Con-
focal microscopy was performed using the Leica TCS SP5
Spectral Confocal Microscope system and the Zeiss LSM
710 confocal laser scanning microscope. Images were ana-
lyzed with the Image J software.
Nucleus staining of HT1080 tumors excised from
mouse xenografts that were left untreated or treated
with MI130110 for 24 h was performed by staining fro-
zen slides of the tumors with a 1:5000 dilution in PBS of
commercial Hoechst 33258 (Sigma-Aldrich).
Xenograft murine models
Design, randomization, and monitoring of experiments
(including body weights and tumor measurements) were
performed using the NewLab Software v2.25.06.00
(NewLab Oncology, Vandoeuvre-Lès Nancy, France). Fe-
male athymic Nude-Foxn-1 nu/nu mice were used to
generate xenografts of HT1080 whereas RPMI 8226 cells
were xenografted in CB-17/IcrHsd-PrKdc-SCID mice,
both mice strains supplied by Envigo, RMS Spain S.L.
Animals between 4 to 6 weeks of age were subcutane-
ously xenografted with each cell into their right flank
with circa 3-30 x 1E06 cells suspended in 0.05 ml of so-
lution consisting of 50% Matrigel™ (Corning Inc., Corn-
ing, NY) and 50% cell culture medium without serum or
antibiotics. When tumors reached circa 200 mm3, mice
(N = 8–20 animals per group) were randomly allocated
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(Day 0) to receive the intended dose of MI130110,
PM050489, anti-CD13 mAb, or vehicle. Intravenous
treatments were weekly administered for 2 consecutive
weeks. The control animals received an equal volume of
vehicle with the same schedule. Caliper measurements
of the tumor diameters were made three times a week,
and tumor volumes were calculated according to the fol-
lowing formula: Volume = (a × b2)/2, where a and b
were the longest and shortest tumor diameters, respect-
ively. For survival evaluation, time to endpoint was de-
fined as the time from day 0 to death as a result of
tumor growth (larger than 2000mm3) or any other cause
(e.g., tumor necrosis). Complete tumor regression (CR)
was defined as tumor volume below 63mm3 for 2 or
more consecutive measurements, such value corre-
sponding to the lowest measurable limit considering the
contribution of the mass from fibrous material, scar tis-
sue, etc. Statistical differences, in animal survival, were
assessed by Kaplan-Meier curves with the log rank test.
Animals were humanely sacrificed when their tumors
reached 2500mm3 or if significant toxicity (e.g., severe
body weight reduction) was observed. Differences in
tumor volumes between treated and control group were
evaluated using the Mann–Whitney U-test. Statistical
analyses were performed by Graph Pad Prism® v5.03
(Graph Pad Software Inc. La Jolla, CA, USA).
Results
Cellular uptake of TEA1/8 and MI130110 upon interaction
with CD13
Several human cell lines were examined to assess the ex-
pression levels of CD13 on their surface in order to se-
lect the most appropriate ones to perform our studies.
As observed in Fig. 1b, flow cytometry data revealed that
HT1080 (fibrosarcoma), U-937 (histiocytic lymphoma),
and NB-4 (acute promyelocytic leukemia) cells showed
high levels of CD13, whereas CD13 expression could not
be detected in Raji (Burkitt’s lymphoma), RPMI 8226
(myeloma), and EA.hy926 (endothelium, non-tumor)
cells. In addition to these immortalized cell lines, CD13
expression is found in normal tissues in cells from the
myeloid lineage. Accordingly, CD13 levels were very
prominent in some representative examples of acute
myeloid leukemia and myeloid sarcoma (Suppl. Fig. 1 a-
c). In addition, CD13 has been described to be expressed
in a variety of tumors of distinct origin. Indeed, we show
CD13 expression in a variety of tumors, including a sam-
ple of well-differentiated liposarcoma and another of
dedifferentiated liposarcoma (Suppl. Fig. 1 d and e, re-
spectively), a specimen of signet ring cell gastric adeno-
carcinoma (Suppl. Fig. 1f), and in two samples of ductal
carcinoma (Suppl. Fig. 1 g and h). Interestingly, we have
also observed CD13 expression on the endothelium of
tumor blood vessels of a breast tumor sample with
tumor cells lacking CD13 expression (Suppl. Fig. 1 i),
confirming previous reports [7] and further stressing the
potential of this protein as a possible tumor target.
Next, the CD13-expressing cell lines U-937, HT1080,
and NB-4 were then tested for their ability to internalize
the TEA1/8-CD13 complex. Figure 2a shows a signifi-
cant degree of internalization after a 3-h incubation of
the cells with the antibody. Such cellular uptake can be
quantified by measuring the decrease in MFI and
accounted for a CD13 internalization of 75% for U-937,
51% for HT1080, and 54% for NB-4 of the total amount
of CD13 normally expressed on the cell surface. The
event was also visualized by fluorescence microscopy
(Fig. 2b) with HT1080 cells: while at t = 0, most of the
antibody remained bound to the plasma membrane, after
3 h a relevant portion of it can be detected as fluorescent
spots within the cytosol, thus confirming that CD13 was
indeed endocytosed and not lost by a proteolytic shed-
ding mechanism.
The significant internalization rate of the antibody cer-
tainly endorses the suitability of CD13 as a possible ADC
target, but it also led us to consider whether the conjuga-
tion of the antibody with PM050489 may affect such effi-
cient uptake. The drug was conjugated to TEA1/8 as
described under the “Methods” section and in the supple-
mentary information (structure in Fig. 1a), and the per-
formance of the conjugation was checked by HIC (Suppl.
Fig. 2). Several peaks of higher hydrophobicity than that of
the naked antibody (hence, suggesting the presence of sev-
eral species of conjugates with different stoichoimetries)
could be detected, confirming the success of the conjuga-
tion process. The new ADC, termed MI130110, was then
tested for its ability to bind to CD13 in HT1080 cells and
to promote the endocytosis of the antibody-antigen com-
plex. According to Fig. 2c, both ADC and antibody bind
to CD13 expressed on the surface of HT1080 cells with
identical affinities (2.1 ± 0.3 nM for the ADC and 2.3 ±
0.3 nM for the antibody), thus demonstrating that the
conjugation to PM050489 did not affect the ability of the
antibody to bind its target. Notably, such binding reaches
saturation at high concentrations, thus highlighting the
specific nature of the binding. Moreover, flow cytometry
experiments evidenced that MI130110 is readily endocy-
tosed by HT1080 cells: 60% of the ADC is internalized in
the HT1080 cells after 4 h incubation as calculated from
the decrease of the MFI (Fig. 2d), a value similar to that
rendered by the unconjugated antibody (58%) in the same
experiment. This decrease in the antibody labeling on the
cell surface is due to cellular uptake and not to spontan-
eous release to the milieu, as demonstrated above. The
similar rate and efficiency of CD13 endocytosis induced
by both anti-CD13 TEA1/8 mAb and MI130110 ADC is
further confirmed by the similar amounts of both mole-
cules remaining in the culture supernatant after 24 h of
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Fig. 2 Cellular uptake of TEA1/8 and MI130110. a HT1080, U-937, and NB-4 cells (1E06) kept in suspension were incubated with TEA1/8 (10 μg/
mL) for 3 h at 37 °C. Cells were then washed with cold PBS, labeled with rabbit anti-mouse FITC on ice for 30 min, and analyzed by flow
cytometry. Cells labeled with isotype control were used as negative control. The percentage of CD13 endocytosis was calculated as the decrease
of MFI of CD13 staining after 3 h incubation at 37 °C relative to the CD13 MFI at t = 0. b HT1080 cells (1E05) were plated in complete tissue
culture medium onto poly-lysinated cover glasses and allowed to settle for 24 h at 37 °C and 5% CO2. Then, cells were left untreated or
incubated with 5 μg/mL TEA1/8 for 3 h at 37 °C. Cells were fixed with 1:1 (v/v) methanol/acetone, washed, and labeled with rabbit anti-mouse
FITC. Nuclei were visualized by DAPI staining. Figure shows untreated cells (t = 0), and cells allowed to internalize CD13 for 3 h (t = 3h). Samples
were analyzed by confocal microscopy. Scale bars are shown. c HT1080 cells (1E06) were incubated with the indicated concentrations of TEA1/8
or MI130110 for 30 min on ice. After washing, cells were labeled with rabbit anti-mouse FITC and analyzed by flow cytometry. The resulting data
were used to calculate the binding affinities of both molecules to CD13 by non-linear regression fitting of the experimental data to a classical
binding isotherm equation considering one class of binding sites, the curves shown in the graph correspond to such regression. d HT1080 cells
(1E06) were incubated in suspension with 10 μg/mL of either TEA1/8 or MI130110 at 37 °C for 4 h. Once washed, cells were labeled with rabbit
anti-mouse FITC and analyzed by flow cytometry. Cells labeled with isotype control were used as negative control. The percentage of
endocytosis at 4 h was calculated as the decrease of the MFI of CD13 staining after 4 h incubation at 37 °C relative to the CD13 MFI at t = 0.
e HT1080 cells (1E06) were incubated in 200 μL culture medium with the indicated concentrations of TEA1/8 or MI130110 for 12 h at 37 °C to
allow endocytosis to proceed. Then, 100 μL of the supernatants were harvested and used to stain CD13 on fresh HT1080 cells (1E06) as described
for c. Concentrations in the horizontal axis correspond to those initially used in the first incubation
Domínguez et al. Journal of Hematology & Oncology           (2020) 13:32 Page 6 of 15
culture with HT1080 cells. Indeed, as shown in Fig. 2e,
when the harvested supernatants are tested for binding to
fresh HT1080, both TEA1/8 mAb and MI130110 superna-
tants produced identical binding curves although with
lower amplitude compared to Fig. 2c, thus indicating that
similar amounts of both unconjugated anti-CD13 mAb
and MI130110 ADC were endocytosed by the cells.
Biological effects of MI130110 in vitro
The above results support the suitability of CD13 as an
ADC target and thus encourage testing the biological ac-
tivity of the ADC based on the anti-CD13 antibody. The
in vitro anti-proliferative effect of MI130110 was evaluated
against tumor cells expressing CD13 (HT1080, NB-4, and
U-937) or not (Raji and RPMI 8226). The MI130110 ADC
showed a clear anti-proliferative potential with remarkable
selectivity for CD13-expressing cells (Table 1 and Fig. 3a),
and both features were exclusive of the ADC molecule
since PM050489 showed potent activity but not selectivity
(Supplementary Table 1), whereas the naked TEA1/8
mAb did not cause any effect on the growth of any of the
tested cell lines up to the highest concentration tested
(1 μg/mL). Therefore, MI130110 combines the antitumor
potential of the PM050489 payload with the selectivity of
the anti-CD13 TEA1/8 mAb.
To further endorse CD13 as a valid ADC target, we
decided to confirm the appropriate intracellular process-
ing of the MI130110-CD13 complex by interrogating
whether the ADC payload was responsible for the anti-
proliferative activity of MI130110, thus demonstrating
an adequate intracellular payload release. The chemical
class represented by PM050489 (including its dechlori-
nated analog, plocabulin, which is currently undergoing
clinical trials for solid tumors) is known to bind tubulin
tightly, thus impairing microtubule dynamics and cell
division which will eventually result in cell death [31].
Therefore, the effect of the ADC on cell cycle was inves-
tigated. The flow cytometry data presented in Fig. 3b
show that MI130110 arrested the cell cycle of fibrosar-
coma HT1080 cells in G2 in a concentration-dependent
manner since, according to the ratio of the peak areas,
the percentage of cells in G2 rose from basal levels in
the absence of ADC (22% at 24 h and 19% at 48 h) to
34% (24 h) or 31% (48 h) at 1 μg/mL to 54% (24 and 48
h) at 10 μg/mL. In contrast, MI130110 did not induce
any effect on the cell cycle of the CD13-negative non-
tumor endothelial EA.hy926 cells as the percentage of
cells in G2 did not change with time (24 or 48 h) in the
presence or in the absence of the ADC concentrations
under study (1 μg/mL and 10 μg/mL), remaining at basal
levels (Fig. 3b, right hand panels). Furthermore, fluores-
cence microscopy images of HT1080 cells treated with
MI130110 for 24 h show the accumulation of cells under-
going mitosis, as indicated by chromosome condensation
and spindle formation (identified by bright β-tubulin
staining) (Fig. 3C). The percentage of cells undergoing
and/or arrested in mitosis in MI130110-treated HT1080
cells was 46%, while in cells treated with anti-CD13
TEA1/8 mAb only 6.5% of them were dividing (Fig. 3d).
This result is consistent with that obtained in cell cycle
analysis (Fig. 3b) and is in agreement with the mechanism
of action of the payload. In addition, dividing TEA1/8
mAb-treated cells could be found at different stages of mi-
tosis (Fig. 3c, see arrows) while dividing MI130110-treated
cells seem to be arrested at the earlier stages of mitosis. A
more detailed analysis of the effect of MI130110 in mitosis
demonstrated that chromosomes were fully condensed
and that the nuclear membrane was disintegrated (Suppl
Fig. 3), centrioles have moved, and the spindle formation
was initiated (Fig. 3e). However, MI130110 treatment
caused striking microtubule misalignment and mitotic spin-
dle disarray, including frequent multipolar spindles, and the
chromosomes failed to align in the equatorial plane (Fig. 3e).
The failure of dividing cells to progress from methaphase
would eventually result in mitotic catastrophe-mediated cell
death. In contrast, none of these abnormalities was observed
in anti-CD13 TEA1/8 mAb-treated cells, which could form
normal spindles and aligned chromosomes and successfully
completed mitosis (Fig. 3e).
It is noteworthy that, as shown in Fig. 3e, CD13 was
endocyted and found in cytosolic vesicles away from the
mitotic apparatus, thus further confirming that the pay-
load was successfully released from the ADC.
Accordingly, treatment with 10 μg/mL MI130110
seems to induce cell death only in CD13-expressing cells
(HT1080 and U-937) but not in CD13-null cells
(EA.hy926 and Raji) according to the flow cytometry ex-
periment shown in Fig. 4. Of note, the fluorescent signal
due to annexin V-FITC preceded that of PI in U-937
cells, thus suggesting apoptosis, but annexin V and PI
staining were instead simultaneous in HT1080 which is
suggestive of necrosis, two types of cell death that can
occur after a mitotic catastrophe [32]. In contrast, only
residual hints of cell death could be observed in the cell
lines not expressing CD13. Together, these results
Table 1 Anti-proliferative activity of MI130110 in CD13-positive
and negative cell lines. Values represent the geometric mean of
three or more different experiments, each performed in
triplicate
Tumor cell line Cancer type CD13 status IC50 (μg/mL) GSD
HT1080 Fibrosarcoma Positive 0.17 1.32
NB-4 Leukemia Positive 0.10 3.5
U-937 Lymphoma Positive 0.14 3.3
RPMI 8226 Myeloma Negative > 1.0 -
Raji Lymphoma Negative > 1.0 -
. IC50 concentration that inhibits cell growth by 50%, GSD geometric
standard deviation
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Fig. 3 (See legend on next page.)
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Fig. 3 Effects of MI130110 on cell division. a Anti-proliferative assay showing the in vitro potency of MI130110. The assay was performed as
described in the “Materials and methods” section with CD13-positive U-937 (solid circles), NB-4 (solid squares) and HT1080 (solid triangles) cell
lines and CD13-negative RPMI 8226 (hollow circles) and Raji (hollow squares) cell lines. b HT1080 and EA.hy926 were cultured in the presence of
different concentration of MI130110 (0, 1, and 10 μg/mL) for 24 and 48 h. Then, 2E06 cells were harvested, fixed in ethanol and their nuclei
stained with PI, and analyzed by cytofluorimetry. The percentage values shown correspond to the percentage of cells in G2 phase. c HT1080 cells
were incubated with either anti-CD13 TEA1/8 mAb (5 μg/mL) or MI130110 (5 μg/mL) for 24 h at 37 °C and processed as described in the
“Materials and methods” section. The expression of β tubulin, DAPI-staining of DNA, and a merged composition of representative fields of cells
treated with anti-CD13 mAb and ADC is shown. Scale bars are shown. d Quantification of cells in interphase and mitosis after 24 h treatment
with anti-CD13 TEA1/8 mAb (5 μg/mL) or MI130110 (5 μg/mL). Cells were processed as described in c. Cells in interphase or undergoing mitosis
from a total of 7 representative fields (24 x optical magnification) for each condition were counted. A total of 539 (93.5%) cells were in interphase
and 20 (6.5%) in mitosis in the treatment with anti-CD13 TEA1/8 mAb. A total of 215 (54%) cells were in interphase and 185 (45%) in mitosis in
the treatment with MI130110. e MI130110 treatment causes mitotic catastrophe. Cells were treated and processed for immunofluorescence as
described in the “Materials and methods” section. Figure shows representative cells undergoing mitosis (128 x optical magnification) treated
either with MI130110 or with naked anti-CD13 TEA1/8 mAb. Staining of CD13 (red), α-tubulin and acetylated α-tubulin (purple), β-tubulin (green)
and chromosomes (blue), and a fluorescence merged image (merge) is shown. Scale bars are shown
Fig. 4 Effects of MI130110 on cell death. HT1080, U-937, EA.hy926, and Raji cells were cultured in the absence or in the presence of 10 μg/mL
MI130110. Cells were analyzed by flow cytometry and representative dot plots of the annexin V- FITC and PI staining at the indicated times are
shown. Figures show the percentage of cells in every quadrant
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demonstrate that the selective, CD13-dependent cyto-
toxic effect of MI130110 is exclusively due to its payload
and it, in fact, demonstrates the proper intracellular pro-
cessing of the ADC-antigen complex, thus reinforcing
the role of CD13 as a suitable ADC target.
In vivo effects of MI130110
Based on this in vitro evidence of the potential antitumor
effect of the CD13-targeting ADC, we next investigated
whether it could be translated to an in vivo setting using
mouse xenograft models of human tumors expressing
CD13. The efficacy of the molecule was tested in xeno-
grafts models of fibrosarcoma (HT1080 cells) or myeloma
(RPMI 8226 cells) expressing or not CD13, respectively.
CD13 expression levels in cells from these tumors were
confirmed by flow cytometry 24 h after the first adminis-
tration to check that such expression had not been altered
after tumor implantation (Suppl. Fig. 5). At the drug doses
used in the experiment, no significant toxicity or body
weight loss was observed in the treated animals. As shown
in Fig. 5a, MI130110 up to 20mg/kg did not elicit any an-
titumor activity in the RPMI 8226 myeloma xenograft
model due to the negligible expression of CD13 by these
cells (Fig. 1b and Suppl. Fig 5). Since PM050489 showed a
potent effect in this model at a very low dose (80 μg/kg),
the lack of response to the ADC treatment demonstrates
that there is no spontaneous release of the payload in blood.
However, as observed in Fig. 5b, MI130110 induced a
strong antitumor response in the CD13-expressing
HT1080 fibrosarcoma model. Animals treated with 5, 10,
or 20mg/kg experienced complete tumor remissions dur-
ing the treatment (Fig. 5b and Suppl. Fig. 5). Hence, 8 out
of 20 animals treated with MI130110 at 5mg/kg experi-
enced complete remissions from days 14 to 28, and 3 out
of 20 animals in this group remained in tumor remission
beyond day 390. All animals treated with MI130110 at 10
mg/kg experienced complete remissions from days 9 to 21,
and 11 out of 20 animals in this group still had tumor re-
mission beyond day 230. Finally, all animals treated with
MI130110 at the highest dose (20mg/kg), experienced
complete remissions from days 7 to 28, and 17 out of 20
animals in this group were tumor-free beyond day 330.
Likewise, PM050489 also induced anti-tumoral activity in
animals treated with this compound at 0.075mg/kg (Fig.
5b), although systemic toxicity was observed, and therefore
treatments were discontinued and animals sacrificed after
day 23. On the other hand, treatment with the anti-CD13
TEA1/8 mAb did not cause any response. Survival curves
demonstrated that treatment with MI130110 at 5, 10, or
20mg/kg increased the survival time with statistically sig-
nificant differences regarding the placebo-, PM050489-, or
anti-CD13-treated animals (Fig. 5c). Remarkably, nuclear
staining of HT1080 tumor samples from animals treated
with MI130110 at any dose showed an increase in the
number of mitotic catastrophes significantly higher than
those observed in samples from the placebo-treated group
(Fig. 5d), which is consistent with the mechanism of action
of PM050489, hence confirming that the antitumor re-
sponse caused by the ADC in vivo is due to the activity of
its payload. Altogether, these results clearly demonstrate
that the anti-CD13-based ADC MI130110 is endowed with
extraordinary antitumor potential both in vitro and in vivo,
and therefore CD13 can be deemed as a promising novel
target for the development of ADCs for anticancer therapy.
Discussion
Being an emergent drug class, antibody-drug conjugates
are widely considered as an attractive opportunity to im-
prove the selectivity of cancer therapies. The successful
cases of the four ADCs approved by the FDA to date
[18] have fostered the search of novel entities endowed
with similar beneficial properties. The nature of the anti-
body target constitutes the keystone for selectivity
which, by itself, constitutes the most innovative and
valuable feature of ADCs. Not surprisingly, the search
for novel ADC targets is one of the most compelling
areas of research in the field.
CD13 expression is fairly restricted to the myeloid lineage.
Although CD13 depositions are also found in the luminal re-
gion of the digestive system and on the apical zone of cells
conforming the efferent conducts of some digestive glands,
prostate, and on renal tubules (www.proteinatlas.org), this
apical CD13 expression of luminal epithelial cells should not
be readily accessible by the ADC. Regarding CD13 expres-
sion in tumors, CD13 mRNA and protein seems to be ab-
normally overexpressed, i.e., in some samples of the
melanoma, glioma, lung, liver, pancreatic, stomach, renal,
prostate, testis, endometrial, and ovarian cancers [33, 34]
(data from The Human Protein Atlas available at www.pro-
teinatlas.org). Indeed, there is a very active research on
tumor stratification based on CD13 expression, and there
are many reports in the literature indicating that CD13 ex-
pression is an unfavorable prognosis factor in a variety of
cancers. Those tumors include pancreas [10] and colon can-
cers [11], non-small cell lung cancer [12, 13], malignant
pleural mesothelioma [14], hepatoblastoma [15], hepatocellu-
lar carcinoma [35], clear cell papillary renal cell carcinoma
[36], scirrhous gastric cancer [37], lymphoplasmatic lymph-
oma [38], and soft tissue sarcoma [16]. Some of these tumors
are rare and/or have poor prognosis, and new therapeutic
approaches are urgently needed to increase patient’s survival.
In addition, CD13-targeted therapies would likely
broadly benefit patients with various types of myeloid
malignancies [39], in particular for those with lower sur-
vival rate, such as acute myeloid leukemia, the most
common acute leukemia in adults, with 17% survival rate
at 5 years. Myelodysplastic and myeloproliferative neo-
plasms, including chronic myeloid leukemia, with an
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overall 20% 5-year survival rate [40] are also potential
targets of this ADC.
Furthermore, CD13 is also found in vascular endothe-
lium surrounding tumors [7] (Suppl. Fig. 1), where it
plays a critical role in angiogenesis [4]. This differential
expression pattern with respect to healthy tissues makes
of CD13 an attractive target for the selective delivery of
drugs or cytokines. Indeed, a CD13-specific single
monomeric variable antibody domain tagged to tumor
necrosis factor (TNF) or interferon (IFN)-γ has been
used to kill tumors by targeting the tumor neovascula-
ture [41]. In addition, peptides based in the NGR motif,
found out in a phage display exercise to selectively bind
CD13 [42], have already been tested in “tumor homing”
strategies for chemotherapeutic agents (compiled in [3])
directed towards CD13-expressing cells. Such peptide
sequence was used for conjugation with drugs like doxo-
rubicin [43], cisplatin [44], and lidamycin [45] in experi-
mental preclinical models, and conjugates to human
TNF [46] or tissue factor [47] have even entered clinical
trials. Likewise, such sequence has been used for the
preparation of a prodrug of melphalan (melflufen or
“J1”, [3]) which is currently undergoing clinical trials for
multiple myeloma. Of note is that a single CD13-specific
single-chain V-Ig-fragment (scFv13) linked to exotoxin
A from Pseudomonas aeruginosa has been probed to in-
hibit proliferation of human cancer cell lines in vitro
[48]. However, development of standard ADC targeting
CD13 has been neglected. This might have been the re-
sult of the availability of alternative approaches to target
CD13 that would not require mAb humanization, as de-
scribed above, but it might have also been influenced by
the limited available information regarding the internaliza-
tion efficiency of the antibody-CD13 complex and its sub-
sequent intracellular processing. Our results demonstrate
that the monoclonal TEA1/8 antibody is readily internal-
ized upon interaction with its target in CD13-expressing
cells like HT1080, NB-4, and U-937, with more than 50%
internalization rate after 3 h, and this efficiency remains
unaltered after conjugation with PM050489. The internal-
ization rates that can be inferred from these results are
comparable to those described for other ADCs. Indeed,
when compared to the values published for benchmarking
ADCs and antibodies, the internalization rates of TEA1/8
mAb and MI130110 are faster than those reported for
trastuzumab alone [49, 50], maytansinoid-trastuzumab
conjugates [51], or brentuximab vedotin [52], and it is in
the same range than the internalization rate described for
gemtuzumab ozogamicin [53, 54]. Of note is that the re-
ported internalization rates of the anti-epidermal growth
factor receptor (EGFR) antibody Ab033 are about 10-fold
faster than those reported for the above mentioned conju-
gates [55]. However, it is commonly accepted that an ex-
cessively fast cellular uptake may jeopardize the
therapeutic efficiency of the ADC by hampering tumor
penetration [56]. Therefore, the intermediate internaliza-
tion rates shown by TEA1/8 and MI130110, in a similar
range to that of Mylotarg, seem to be adequate for the
intended use.
Likewise, the moderately high affinity (circa 2 nM)
shown by TEA1/8 and MI130110 is certainly weaker than
that observed for other ADC-related antibody-antigen
pairs falling in the pM scale like gemtuzumab [57], but in
a similar range to that described for trastuzumab [58, 59]
or brentuximab [60]. As explained above regarding cellu-
lar uptake, extremely high affinities usually lead to low
therapeutic efficacies [61], as they are associated with slow
off-rates [62], hence deficient ADC release and poor intra-
cellular processing as well as impaired tumor penetration
[63]. Consequently, the moderately high affinity of TEA1/
8 mAb for CD13, matching those of the Kadcyla and
Adcetris antibodies for their targets, together with the
mild internalization rate similar to that of Mylotarg, en-
dorse CD13 as a suitable ADC target and TEA1/8 mAb as
a valid antibody for conjugation purposes.
The antitumor properties exhibited by MI130110
in vitro and in vivo, with the excellent results obtained
in the murine xenograft models, support these argu-
ments. MI130110 caused a remarkable antitumor effect
in the fibrosarcoma HT1080 model leading to complete
tumor remissions that lasted beyond 1 year in a signifi-
cant proportion of the treated animals. The lack of activ-
ity observed in the CD13-negative RPMI 8226 myeloma
model demonstrates that payload release does not occur
spontaneously, while the appearance of mitotic catastro-
phes (consistent with the mechanism of action of the
PM050489 payload) in HT1080 tumor cells observed
both in vitro and in tumors from xenografted animals
(See figure on previous page.)
Fig. 5 Biological effects of MI130110 in vivo. Animals (8–20 per group) were treated weekly for five consecutive weeks with either MI130110 at 5
(hollow triangles), 10 (pink inverted triangles), or 20 (red triangles) mg/kg, TEA1/8 at 20 mg/kg (blue circles), PM050489 at 80 μg/kg (black squares)
or vehicle (hollow circles) following the procedure described in the “Materials and methods” section in mice xenografted with RPMI 8226 (a) or
HT1080 (b and c) tumor cells. a and b show tumor growth evolution (with inset in b detailing HT1080 tumor evolution during the first 25 days),
and c shows Kaplan-Meier survival curves for HT1080 xenografted animals. d Immunofluorescence analysis of tumor samples, withdrawn 24 h
after the first treatment from mice xenografted with HT1080 tumor cells and treated with vehicle or with 5, 10, or 20 mg/kg MI130110, showing
DNA staining with Hoechst 33258. Figures shown on the right hand side of each panel indicate the average (plus and minus the standard
deviation) of the number of mitotic catastrophe nuclei per five high-power fields, with magnification being × 40
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that had been treated with MI13010 indicates an ad-
equate intracellular processing of the ADC in CD13-
expressing cells, therefore confirming that conjugation
to TEA1/8 mAb does not hinder the anti-proliferative
properties of the marine drug.
Finally, it is important to mention that secondary or
acquired resistance to anti-mitotic drugs is often related
to the upregulation membrane efflux pumps of the
ATP-binding cassette (ABC) family that actively exports
out of the cell the cytotoxic compounds [64, 65]. By
using the MI130110 ADC and, therefore, altering the
entry pathway of the anti-mitotic PM050489 drug to the
cell, the efficacy of the ABC family might be reduced,
allowing the drug to be effective in tumor cells with this
type of resistance.
In overall, the results presented in this study demonstrate
that CD13 is a suitable target for the development of novel
ADCs of promising therapeutic potential in the fight
against cancers of different origin and poor prognostic.
Conclusions
In this report, we have described for the first time the gen-
eration of an anti-CD13 mAb-based ADC, MI130110.
Our results on the specificity and activity of MI130110,
both in vitro and in vivo demonstrate that it combines the
strong antitumor activity of the PM050489 payload with
the selectivity of the anti-CD13 TEA1/8 mAb and have
confirmed the correct intracellular processing of the ADC.
Altogether, our results demonstrate the suitability of
CD13 as a novel ADC target and the effectiveness of
MI130110 as a promising antitumor therapeutic agent.
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